Zermatten A, Heptner W, Delaloye B, Séchaud R, Felber J P
Diabetologia. 1977 Apr;13(2):85-8. doi: 10.1007/BF00745132.
Experiments were performed in order to study a possible participation of gastrointestinal factors in the insulinotrophic action of glibenclamide in man. Six healthy volunteers received 5 mg glibenclamide in 50 ml saline orally. Biopsies were taken from the duodenal mucosa before and after administration of the drug. The duodenal insulin-releasing activity (DIRA) was assayed in the extracts of the biopsy material by using an in situ pancreas preparation of rat. The corresponding drug, IRI and glucose levels were measured in peripheral blood. The values of IRI correlated with both the prior elevation of DIRA and the increasing levels of the drug in the blood. These data indicate that glibenclamide might stimulate the release of gut factor(s) which, in turn, could possibly sensitize the pancrease response to the drug.
进行实验以研究胃肠道因素是否可能参与格列本脲对人体的促胰岛素作用。六名健康志愿者口服50毫升盐水中含5毫克格列本脲。在给药前后从十二指肠黏膜取活检组织。通过使用大鼠原位胰腺制剂,在活检材料提取物中测定十二指肠胰岛素释放活性(DIRA)。在外周血中测量相应的药物、胰岛素和葡萄糖水平。胰岛素水平与DIRA先前的升高以及血液中药物水平的增加均相关。这些数据表明,格列本脲可能刺激肠道因子的释放,而肠道因子反过来可能使胰腺对该药物的反应敏感。